Your browser doesn't support javascript.
loading
Increased Prevalence of Rare Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Patients.
Garcia-Etxebarria, Koldo; Zheng, Tenghao; Bonfiglio, Ferdinando; Bujanda, Luis; Dlugosz, Aldona; Lindberg, Greger; Schmidt, Peter T; Karling, Pontus; Ohlsson, Bodil; Simren, Magnus; Walter, Susanna; Nardone, Gerardo; Cuomo, Rosario; Usai-Satta, Paolo; Galeazzi, Francesca; Neri, Matteo; Portincasa, Piero; Bellini, Massimo; Barbara, Giovanni; Jonkers, Daisy; Eswaran, Shanti; Chey, William D; Kashyap, Purna; Chang, Lin; Mayer, Emeran A; Wouters, Mira M; Boeckxstaens, Guy; Camilleri, Michael; Franke, Andre; D'Amato, Mauro.
Afiliación
  • Garcia-Etxebarria K; Department of Gastrointestinal and Liver Diseases, Biodonostia Health Research Institute, San Sebastián, Spain; Unit of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Zheng T; Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Bonfiglio F; Department of Gastrointestinal and Liver Diseases, Biodonostia Health Research Institute, San Sebastián, Spain; Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.
  • Bujanda L; Department of Gastrointestinal and Liver Diseases, Biodonostia Health Research Institute, San Sebastián, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco (UPV/EHU), San Sebastián, Spain.
  • Dlugosz A; Department of Medicine Solna, Karolinska Institutet, Center for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Lindberg G; Department of Medicine Solna, Karolinska Institutet, Center for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Schmidt PT; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco (UPV/EHU), San Sebastián, Spain.
  • Karling P; Division of Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
  • Ohlsson B; Lund University, Skåne University Hospital, Department of Internal Medicine, Lund, Sweden.
  • Simren M; Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Walter S; Division of Neuro and Inflammation Science, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
  • Nardone G; Gastroenterology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
  • Cuomo R; Digestive Motility Diseases, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy.
  • Usai-Satta P; S.C. Gastroenterologia, Azienda Ospedaliera G. Brotzu, Cagliari, Italy.
  • Galeazzi F; UOC Gastroenterologia, Padova University Hospital, Padova, Italy.
  • Neri M; Department of Medicine and Aging Sciences and CESI, G. D'Annunzio University and Foundation, Chieti, Italy.
  • Portincasa P; Department of Biomedical Sciences and Human Oncology (DIMO), Clinica Medica "A. Murri", University of Bari Medical School, Bari, Italy.
  • Bellini M; Gastroenterology Unit, Department of Gastroenterology, University of Pisa, Pisa, Italy.
  • Barbara G; Department of Medical and Surgical Sciences, University of Bologna, St Orsola - Malpighi Hospital, Bologna, Italy.
  • Jonkers D; Department of Internal Medicine, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Eswaran S; Division of Gastroenterology, University of Michigan, Michigan Medicine, Ann Arbor, Michigan.
  • Chey WD; Division of Gastroenterology, University of Michigan, Michigan Medicine, Ann Arbor, Michigan.
  • Kashyap P; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
  • Chang L; G. Oppenheimer Center for Neurobiology of Stress and Resilience, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California.
  • Mayer EA; G. Oppenheimer Center for Neurobiology of Stress and Resilience, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California.
  • Wouters MM; Translational Research Center for Gastro Intestinal Disorders (TARGID), KU Leuven, Leuven, Belgium.
  • Boeckxstaens G; Translational Research Center for Gastro Intestinal Disorders (TARGID), KU Leuven, Leuven, Belgium.
  • Camilleri M; Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), and Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
  • Franke A; Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.
  • D'Amato M; Department of Gastrointestinal and Liver Diseases, Biodonostia Health Research Institute, San Sebastián, Spain; Unit of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden; IKERBASQUE,
Clin Gastroenterol Hepatol ; 16(10): 1673-1676, 2018 10.
Article en En | MEDLINE | ID: mdl-29408290
ABSTRACT
Patients with irritable bowel syndrome (IBS) often associate their symptoms to certain foods. In congenital sucrase-isomaltase deficiency (CSID), recessive mutations in the SI gene (coding for the disaccharidase digesting sucrose and 60% of dietary starch)1 cause clinical features of IBS through colonic accumulation of undigested carbohydrates, triggering bowel symptoms.2 Hence, in a previous study,3 we hypothesized that CSID variants reducing SI enzymatic activity may contribute to development of IBS symptoms. We detected association with increased risk of IBS for 4 rare loss-of-function variants typically found in (homozygous) CSID patients, because carriers (heterozygous) of these rare variants were more common in patients than in controls.1,4 Through a 2-step computational and experimental strategy, the present study aimed to determine whether other (dys-)functional SI variants are associated with risk of IBS in addition to known CSID mutations. We first aimed to identify all SI rare pathogenic variants (SI-RPVs) on the basis of integrated Mendelian Clinically Applicable Pathogenicity (M-CAP) and Combined Annotation Dependent Depletion (CADD) predictive (clinically relevant) scores; next, we inspected genotype data currently available for 2207 IBS patients from a large ongoing project to compare SI-RPV case frequencies with ethnically matched population frequencies from the Exome Aggregation Consortium (ExAC).
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Complejo Sacarasa-Isomaltasa / Síndrome del Colon Irritable / Frecuencia de los Genes / Genotipo Tipo de estudio: Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Complejo Sacarasa-Isomaltasa / Síndrome del Colon Irritable / Frecuencia de los Genes / Genotipo Tipo de estudio: Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Suecia